I-Tech AB (ITECH.ST)
SEK 77.8
(-0.51%)
SEK 77.8
(-0.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 30.34 Million SEK | 36.47% |
| 2022 | 14.7 Million SEK | 353.3% |
| 2021 | 1.6 Million SEK | 56.75% |
| 2020 | 3.02 Million SEK | 131.24% |
| 2019 | -1.66 Million SEK | 121.94% |
| 2018 | -5.95 Million SEK | 3.81% |
| 2017 | -6.19 Million SEK | -12.65% |
| 2016 | -5.49 Million SEK | 27.86% |
| 2015 | -7.61 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 12.95 Million SEK | 3.97% |
| 2024 Q3 | 11.9 Million SEK | 2.12% |
| 2024 Q1 | 11.2 Million SEK | 636.88% |
| 2023 Q1 | 10.42 Million SEK | 34.08% |
| 2023 FY | - SEK | 36.47% |
| 2023 Q4 | 2.68 Million SEK | -75.17% |
| 2023 Q3 | 10.81 Million SEK | 15.06% |
| 2023 Q2 | 9.39 Million SEK | -9.84% |
| 2022 Q1 | 2.56 Million SEK | 13605.26% |
| 2022 FY | - SEK | 353.3% |
| 2022 Q4 | 7.77 Million SEK | 7.17% |
| 2022 Q3 | 7.25 Million SEK | 87.56% |
| 2022 Q2 | 3.86 Million SEK | 50.7% |
| 2021 Q1 | 2.52 Million SEK | 294.84% |
| 2021 Q3 | 3.2 Million SEK | 427.64% |
| 2021 Q4 | -19 Thousand SEK | -100.59% |
| 2021 FY | - SEK | 56.75% |
| 2021 Q2 | -977 Thousand SEK | -138.63% |
| 2020 Q4 | -1.29 Million SEK | -202.29% |
| 2020 Q3 | 1.26 Million SEK | -37.95% |
| 2020 Q1 | 1.39 Million SEK | 43.19% |
| 2020 FY | - SEK | 131.24% |
| 2020 Q2 | 2.04 Million SEK | 46.18% |
| 2019 Q2 | 1.16 Million SEK | 148.86% |
| 2019 FY | - SEK | 121.94% |
| 2019 Q4 | 977 Thousand SEK | -42.53% |
| 2019 Q3 | 1.7 Million SEK | 46.55% |
| 2019 Q1 | -2.37 Million SEK | -215.69% |
| 2018 Q2 | -93 Thousand SEK | 95.72% |
| 2018 FY | - SEK | 3.81% |
| 2018 Q3 | -2.84 Million SEK | -2954.84% |
| 2018 Q1 | -2.17 Million SEK | -24.57% |
| 2018 Q4 | -752 Thousand SEK | 73.53% |
| 2017 Q3 | -1.35 Million SEK | -54.26% |
| 2017 Q1 | -2.2 Million SEK | 0.0% |
| 2017 Q2 | -881 Thousand SEK | 59.99% |
| 2017 Q4 | -1.74 Million SEK | -28.48% |
| 2017 FY | - SEK | -12.65% |
| 2016 FY | - SEK | 27.86% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 108.25% |
| Camurus AB (publ) | 562.54 Million SEK | 94.606% |
| Mendus AB (publ) | -97.84 Million SEK | 131.013% |
| Lipum AB (publ) | -37.11 Million SEK | 181.751% |
| NextCell Pharma AB | -40.98 Million SEK | 174.039% |
| Simris Alg AB (publ) | -22.36 Million SEK | 235.693% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 277.617% |
| Active Biotech AB (publ) | -43.88 Million SEK | 169.143% |
| Amniotics AB (publ) | -27.14 Million SEK | 211.797% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 313.442% |
| BioArctic AB (publ) | 275.38 Million SEK | 88.981% |
| Cantargia AB (publ) | -284.31 Million SEK | 110.673% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 254.987% |
| CombiGene AB (publ) | -35.33 Million SEK | 185.875% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 121.544% |
| Genovis AB (publ.) | 64.57 Million SEK | 53.006% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 126.408% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 181.96% |
| Intervacc AB (publ) | -68.98 Million SEK | 143.991% |
| Kancera AB (publ) | -61.88 Million SEK | 149.031% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 213.299% |
| LIDDS AB (publ) | -39.67 Million SEK | 176.494% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 350.702% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 3.372% |
| OncoZenge AB (publ) | 7.26 Million SEK | -317.63% |
| Saniona AB (publ) | -69.69 Million SEK | 143.54% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 109.559% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 110.759% |
| Xintela AB (publ) | -53.47 Million SEK | 156.75% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 117.869% |
| Ziccum AB (publ) | -20.34 Million SEK | 249.174% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -1517150.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 112.771% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 1558.894% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 325.933% |
| Corline Biomedical AB | -1.69 Million SEK | 1894.5% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 117.508% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 155.368% |
| Aptahem AB (publ) | -10 Million SEK | 403.17% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | -162.75% |
| Fluicell AB (publ) | -25.91 Million SEK | 217.099% |
| Biovica International AB (publ) | -119.5 Million SEK | 125.392% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 171.867% |
| AcouSort AB (publ) | -16.7 Million SEK | 281.674% |
| Abliva AB (publ) | -93.6 Million SEK | 132.417% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 109.51% |
| 2cureX AB (publ) | -35.13 Million SEK | 186.364% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 104.247% |
| Cyxone AB (publ) | -20.41 Million SEK | 248.648% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 129.618% |
| Biosergen AB | 228 Thousand SEK | -13209.211% |
| Nanologica AB (publ) | -62.11 Million SEK | 148.85% |
| SynAct Pharma AB | -222.7 Million SEK | 113.626% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 169.184% |
| BioInvent International AB (publ) | -312.7 Million SEK | 109.704% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | -9707.28% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -72151.72% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 113.101% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 444.341% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 127.953% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 364.583% |